Literature DB >> 32345652

Acrylamide Exposure and Oxidative DNA Damage, Lipid Peroxidation, and Fasting Plasma Glucose Alteration: Association and Mediation Analyses in Chinese Urban Adults.

Bin Wang1,2, Weihong Qiu1,2, Shijie Yang1,2, Limin Cao1,2, Chunmei Zhu1,2, Jixuan Ma1,2, Wei Li1,2, Zhuang Zhang1,2, Tao Xu1,2, Xing Wang1,2, Man Cheng1,2, Ge Mu1,2, Dongming Wang1,2, Yun Zhou1,2, Jing Yuan1,2, Weihong Chen3,2.   

Abstract

OBJECTIVE: Acrylamide exposure from daily-consumed food has raised global concern. We aimed to assess the exposure-response relationships of internal acrylamide exposure with oxidative DNA damage, lipid peroxidation, and fasting plasma glucose (FPG) alteration and investigate the mediating role of oxidative DNA damage and lipid peroxidation in the association of internal acrylamide exposure with FPG. RESEARCH DESIGN AND METHODS: FPG and urinary biomarkers of oxidative DNA damage (8-hydroxy-deoxyguanosine [8-OHdG]), lipid peroxidation (8-iso-prostaglandin-F2α [8-iso-PGF2α]), and acrylamide exposure (N-acetyl-S-[2-carbamoylethyl]-l-cysteine [AAMA], N-acetyl-S-[2-carbamoyl-2-hydroxyethyl]-l-cysteine [GAMA]) were measured for 3,270 general adults from the Wuhan-Zhuhai cohort. The associations of urinary acrylamide metabolites with 8-OHdG, 8-iso-PGF2α, and FPG were assessed by linear mixed models. The mediating roles of 8-OHdG and 8-iso-PGF2α were evaluated by mediation analysis.
RESULTS: We found significant linear positive dose-response relationships of urinary acrylamide metabolites with 8-OHdG, 8-iso-PGF2α, and FPG (except GAMA with FPG) and 8-iso-PGF2α with FPG. Each 1-unit increase in log-transformed level of AAMA, AAMA + GAMA (ΣUAAM), or 8-iso-PGF2α was associated with a 0.17, 0.15, or 0.23 mmol/L increase in FPG, respectively (P and/or P trend < 0.05). Each 1% increase in AAMA, GAMA, or ΣUAAM was associated with a 0.19%, 0.27%, or 0.22% increase in 8-OHdG, respectively, and a 0.40%, 0.48%, or 0.44% increase in 8-iso-PGF2α, respectively (P and P trend < 0.05). Increased 8-iso-PGF2α rather than 8-OHdG significantly mediated 64.29% and 76.92% of the AAMA- and ΣUAAM-associated FPG increases, respectively.
CONCLUSIONS: Exposure of the general adult population to acrylamide was associated with FPG elevation, oxidative DNA damage, and lipid peroxidation, which in turn partly mediated acrylamide-associated FPG elevation.
© 2020 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32345652     DOI: 10.2337/dc19-2603

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  5 in total

1.  Assessment of the genotoxicity of acrylamide.

Authors:  Diane Benford; Margherita Bignami; James Kevin Chipman; Luisa Ramos Bordajandi
Journal:  EFSA J       Date:  2022-05-05

Review 2.  Acrylamide and Potential Risk of Diabetes Mellitus: Effects on Human Population, Glucose Metabolism and Beta-Cell Toxicity.

Authors:  Jelena Marković Filipović; Jelena Karan; Ivana Ivelja; Milica Matavulj; Milena Stošić
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

3.  Negative Association between Acrylamide Exposure and Metabolic Syndrome Markers in Adult Population.

Authors:  Chun-Chi Hung; Yung-Wen Cheng; Wei-Liang Chen; Wen-Hui Fang
Journal:  Int J Environ Res Public Health       Date:  2021-11-14       Impact factor: 3.390

4.  The Association Between Exposure to Acrylamide and Mortalities of Cardiovascular Disease and All-Cause Among People With Hyperglycemia.

Authors:  Huanyu Wu; Xinyi Sun; Hongyan Jiang; Cong Hu; Jiaxu Xu; Changhao Sun; Wei Wei; Tianshu Han; Wenbo Jiang
Journal:  Front Cardiovasc Med       Date:  2022-07-18

5.  The association between biomarkers of acrylamide and cancer mortality in U.S. adult population: Evidence from NHANES 2003-2014.

Authors:  Wenbo Gu; Jiacheng Zhang; Chunling Ren; Yang Gao; Tongfang Zhang; Yujia Long; Wei Wei; Shaoying Hou; Changhao Sun; Changhong Wang; Wenbo Jiang; Junfei Zhao
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.